Drugs / Timolumab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00871598 | Mar 2009 → Aug 2010 | psoriasis | Biotie Therapies Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00851240 | Feb → Nov 2009 | rheumatoid arthritis | Biotie Therapies Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02239211 | Sep 2015 → Oct 2018 | primary sclerosing cholangitis | University of Birmingham | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Timolumab | “Investigating the safety and activity of the use of BTT1023 (Timolumab), in the treatment of patients with primary sclerosing cholangitis (BUTEO): A single-arm, two-stage,...” PMID 28674140 ↗ Jul 2017 |
| Known as | BTT1023 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00871598 ↗ |
| Action | Inhibit | “evaluate the impact of Vap-1 blockade by BTT1023” NCT02239211 ↗ |
| Modality | Monoclonal antibody | “a human monoclonal antibody (BTT1023)” NCT02239211 ↗ |
| Route | Intravenous | “intravenous” NCT00851240 ↗ |